New combo tackles tough pancreatic cancer
NCT ID NCT02077881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has completed, and results will show whether adding indoximod improves outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indoximod (an experimental immunotherapy) plus gemcitabine and nab-paclitaxel (standard chemotherapy)
What this could lead to
If successful, this combination could improve survival for people with metastatic pancreatic cancer, a disease with very few treatment options.
What could go wrong
This is an early-phase trial, so the added benefit over standard chemo alone is uncertain. The immunotherapy may also increase side effects like fatigue or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Gibbs Cancer Center and Research Institute
Spartanburg, South Carolina, 29303, United States
-
Greenville Health Systems
Greenville, South Carolina, 29605, United States
-
Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
The Vally Hospital
Paramus, New Jersey, 07652, United States
-
The West Clinic
Memphis, Tennessee, 38120, United States
-
University of Kentucy
Lexington, Kentucky, 40536, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States